Search results for "Celecoxib"

showing 10 items of 32 documents

Gene expression profiling of human liver cancer cells following celecoxib tretment

2010

Celecoxibglobal gene expression analysisHCCCOX-2microarray
researchProduct

Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow

2005

The main mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of cycloxygenases COX-1 and COX-2. During recent years, combined 5-LOX/COX-inhibition, interfering with the biosynthesis of both prostaglandins and leukotrienes (LTs), has emerged as a possibility to avoid side effects related to COX-inhibition. The aim of the present study was to investigate if there is a contribution of mechanisms other than the reduction of inflammatory prostaglandins and leukotrienes to the anti-inflammatory effect of the LOX/COX inhibitor licofelone. In a flow chamber assay, licofelone (10-30 microM) dose-dependently decreased both the rolling and adhesion of leukocytes on …

EndotheliumAcetatesPharmacologyBiochemistrychemistry.chemical_compoundCell MovementIn vivoCell AdhesionLeukocytesmedicineHumansCyclooxygenase InhibitorsPyrrolesLipoxygenase InhibitorsRNA MessengerCells CulturedPharmacologybiologyChemistryEndothelial Cellsmedicine.anatomical_structureMechanism of actionImmunologyArachidonate 5-lipoxygenaseCelecoxibbiology.proteinCyclooxygenasemedicine.symptomLicofeloneCell Adhesion MoleculesSelectinmedicine.drugBiochemical Pharmacology
researchProduct

Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production

2004

Increased Abeta42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Abeta42. Among the more potent Abeta42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Abeta42, including multiple COX-2-selective derivatives of two Abeta42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Abeta42. These compounds seem to target the gamma-secretase complex, increasing gamma-secretase-catalyzed production of Abeta42 in vitro. Short-term in vivo studies show that two Abeta42-raising comp…

Enzyme-Linked Immunosorbent AssayEndogenyProtein Serine-Threonine KinasesPharmacologyTransfectionMass SpectrometryGeneral Biochemistry Genetics and Molecular BiologyPresenilinCell LineFenofibrateAlzheimer DiseaseIn vivoEndopeptidasesmedicineAspartic Acid EndopeptidasesHumansImmunoprecipitationCyclooxygenase InhibitorsProtein precursorHypolipidemic AgentsSulfonamidesrho-Associated KinasesAmyloid beta-PeptidesFenofibratebusiness.industryAnti-Inflammatory Agents Non-SteroidalIntracellular Signaling Peptides and ProteinsBrainGeneral Medicinemedicine.diseaseIn vitroEnzyme ActivationBiochemistryCelecoxibPyrazolesFemaleAmyloid Precursor Protein SecretasesAlzheimer's diseaserhoA GTP-Binding ProteinbusinessAntilipidemic Agentmedicine.drugNature Medicine
researchProduct

Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review

2022

Abstract Background Several studies have reported that glucosamine sulfate (GS) can improve knee osteoarthritis (OA) symptomatology. In parallel, the disease-modifying effects of non-steroidal anti-inflammatory drugs (NSAIDs) in knee OA have also been investigated. However, limited literature has reported the combined effect of GS and NSAIDs. The aim of this scoping review is to describe the scope and volume of the literature investigating the potential benefits and synergistic effect of a combination of GS and NSAIDs in patients with knee OA. Methods PubMed and Embase were searched for studies published from inception through April 2022, evaluating the effects of the combination of GS and …

GlucosamineObservational Studies as TopicRheumatologyCelecoxibAnti-Inflammatory Agents Non-SteroidalHumansPainOrthopedics and Sports MedicineCelecoxib Chondroprotective effect Cyclooxygenase 2 inhibitors Glucosamine sulfate Non-steroidal anti-inflammatory drugs OsteoarthritisSynergistic effectsOsteoarthritis KneeRandomized Controlled Trials as Topic
researchProduct

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteo…

2021

This study investigated the possible anti-inflammatory and chondroprotective effects of a combination of celecoxib and prescription-grade glucosamine sulfate (GS) in human osteoarthritic (OA) chondrocytes and their possible mechanism of action. Chondrocytes were treated with celecoxib (1.85 µM) and GS (9 µM), alone or in combination with IL-1β (10 ng/mL) and a specific nuclear factor (NF)-κB inhibitor (BAY-11-7082, 1 µM). Gene expression and release of some pro-inflammatory mediators, metalloproteinases (MMPs), and type II collagen (Col2a1) were evaluated by qRT-PCR and ELISA

Interleukin-1betachondrocytesAnti-Inflammatory AgentsApoptosisPharmacologymedicine.disease_causeNF-κBchemistry.chemical_compoundchondroprotectionoxidative stressSulfonesBiology (General)SpectroscopyCells CulturedGlucosamineglucosamine sulfatebiologycelecoxibChemistrySuperoxideNF-kappa BGeneral MedicineComputer Science ApplicationsChemistrychondrocyteosteoarthritiDrug Therapy Combinationmedicine.symptomInflammation Mediatorsmedicine.drugSignal TransductionNF-BQH301-705.5Cell SurvivalGlucosamine SulfateCatalysisArticleInorganic ChemistrySuperoxide dismutaseNitrilesOsteoarthritismedicineHumansPhysical and Theoretical ChemistryQD1-999Molecular Biologyoxidative streOrganic ChemistryMechanism of actionApoptosisinflammationbiology.proteinCelecoxibCyclooxygenaseOxidative stressInternational Journal of Molecular Sciences
researchProduct

Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor ce…

2010

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Celecoxib (Celebrex®) exhibits antitumor effects in human HCC cells, and its mechanism of action is mediated either by its ability to inhibit cyclooxygenase 2 (COX-2) or by a number of various other COX-2 independent effects. Proteasome inhibitors (PIs) can exert cell growth inhibitory and apoptotic effects in different tumor cell types, including HCC cells. The present study examined the interaction between celecoxib and the PI MG132 in two human liver tumor cell lines HepG2 and HA22T/VGH. Our data showed that each inhibitor reduced proliferation and induced apoptosis in a dose-dependen…

MG132TRB3Programmed cell deathLeupeptinsBlotting WesternApoptosisUPRPharmacologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132medicineHumansViability assayHCCMolecular BiologyCell ProliferationSettore MED/12 - GastroenterologiaGene knockdownSulfonamidesbiologyCyclooxygenase 2 InhibitorsCell growthReverse Transcriptase Polymerase Chain ReactionDrug SynergismCell BiologyHep G2 CellsCOX-2ER stress responseFlow CytometryapoptosiproteasomechemistryApoptosisCelecoxibSettore BIO/14 - Farmacologiabiology.proteinProteasome inhibitorPyrazolesCyclooxygenaseDevelopmental Biologymedicine.drug
researchProduct

Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions

2016

In this study, the influence of the molecular weight of polyvinylpyrrolidone (PVP) on the non-sink in vitro dissolution and in vivo performance of celecoxib (CCX):PVP amorphous solid dispersions were investigated. The dissolution rate of CCX from the amorphous solid dispersions increased with decreasing PVP molecular weight and crystallization inhibition was increased with increasing molecular weight of PVP, but reached a maximum for PVP K30. This suggested that the crystallization inhibition was not proportional with molecular weight of the polymer, but rather there was an optimal molecular weight where the crystallization inhibition was strongest. Consistent with the findings from the non…

MalePolymersChemistry PharmaceuticalBiological AvailabilityPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacylaw.inventionRats Sprague-Dawley03 medical and health sciences0302 clinical medicineIn vivolawmedicineAnimalsOrganic chemistryCrystallizationDissolutionchemistry.chemical_classificationPolyvinylpyrrolidoneChemistrytechnology industry and agriculturePovidoneGeneral MedicinePolymer021001 nanoscience & nanotechnologyRatsAmorphous solidBioavailabilityMolecular WeightSolubilityChemical engineeringCelecoxibCrystallization0210 nano-technologyDispersion (chemistry)Biotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Process parameters of microsphere preparation based on propylene carbonate emulsion-precursors.

2020

This study aimed for a detailed understanding of the impact of different process parameters involved during celecoxib-loaded microsphere preparation based on propylene carbonate emulsion-precursors.Microspheres were prepared by a modified emulsification-solvent extraction method. Performed investigations included polymer solubility and viscosity, microsphere size, morphology and stability, propylene carbonate content as well as celecoxib solid state, content and release.Rough-walled round microspheres with sizes between 21 µm and 122 µm and an internal sponge-like structure filled with residual propylene carbonate (content between 1.9 ± 0.1% and 6.7 ± 0.5% w/w) were obtained. Encapsulation …

Materials sciencePolymersSurface PropertiesChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceBioengineering02 engineering and technologyPolypropylenes030226 pharmacology & pharmacyMicrosphere03 medical and health scienceschemistry.chemical_compound0302 clinical medicineColloid and Surface ChemistryLactic AcidPhysical and Theoretical ChemistryParticle SizeDrug CarriersCalorimetry Differential ScanningViscosityOrganic Chemistry021001 nanoscience & nanotechnologyMicrospheresPLGADrug LiberationchemistryChemical engineeringSolubilityCelecoxibScientific methodPropylene carbonateEmulsionMicroscopy Electron ScanningSolventsEmulsions0210 nano-technologyPolyglycolic AcidJournal of microencapsulation
researchProduct

Cholesterol-Like Effects of Selective Cyclooxygenase Inhibitors and Fibrates on Cellular Membranes and Amyloid-β Production

2007

Strong evidence suggests a mechanistic link between cholesterol metabolism and the formation of amyloid-beta peptides, the principal constituents of senile plaques found in the brains of patients with Alzheimer's disease. Here, we show that several fibrates and diaryl heterocycle cyclooxygenase inhibitors, among them the commonly used drugs fenofibrate and celecoxib, exhibit effects similar to those of cholesterol on cellular membranes and amyloid precursor protein (APP) processing. These drugs have the same effects on membrane rigidity as cholesterol, monitored here by an increase in fluorescence anisotropy. The effect of the drugs on cellular membranes was also reflected in the inhibitory…

Membrane lipidsCHO CellsPharmacologyAmyloid beta-Protein PrecursorMicechemistry.chemical_compoundCricetulusFenofibrateCell Line TumorCricetinaeAmyloid precursor proteinmedicineMembrane fluidityAnimalsAspartic Acid EndopeptidasesCyclooxygenase InhibitorsClofibrateSenile plaquesPharmacologySulfonamidesAmyloid beta-PeptidesFenofibratebiologyCholesterolCell MembraneCholesterolMembranechemistryBiochemistryCelecoxibbiology.proteinPyrazolesMolecular MedicineCyclooxygenaseAmyloid Precursor Protein Secretasesmedicine.drugMolecular Pharmacology
researchProduct

Pyrazolobenzotriazinones Derivatives as COX Inhibitors: Synthesis Biological Activity and Molecular Modeling Studies

2010

Pyrazolylbenzotriazinones are endowed with structural analogy with the COX-2 selective inhibitor celecoxib. Considering that our research group has long been interested in the 3-pyrazolyl-substituted benzotriazinones as anti-inflammatory agents, six new pyrazolylbenzotriazinone derivatives 16a-c and 18a-c have been prepared by reacting the opportune ethyl 5-(2-aminobenzamido)-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate or 5-(2-aminobenzamido)-1-(pyridin-2-yl)-1H-pyrazole-4-carboxyic acid with sodium nitrite in glacial acetic acid. The biological studies revealed a good pharmacological profile for some pyrazolylbenzotriazinones and, in the case of the ethyl 5-(4-oxo-1,2,3-benzotriazin-3(4H)-y…

Models MolecularMolecular modelAnti-Inflammatory AgentsPharmaceutical Science2-(1H-pyrazol-1-yl)pyridines 4(3H)-Benzotriazinones docking COX-2 inhibitorsCOX-2 inhibitorschemistry.chemical_compoundAcetic acidStructure-Activity Relationship4(3H)-BenzotriazinonesDrug DiscoverymedicineStructure–activity relationshipOrganic chemistryHumansSodium nitriteSulfonamidesCyclooxygenase 2 InhibitorsTriazinesBiological activitySettore CHIM/08 - Chimica FarmaceuticachemistryDocking (molecular)CelecoxibCelecoxibSettore BIO/14 - FarmacologiaPyrazolesSelectivitymedicine.drug
researchProduct